GlycoMimetics, Inc. (renamed Crescent Biopharma, Inc., June 2025)

CBIO · Nasdaq · United States

Share price · CBIO

$12.40-4.29 (-25.70%) 3M

close as of 2026-11-18 · 24h delayed · vol 327K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CBIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Sep 2026-13.7%

    Nothing announced by CBIO that day or the session before.

  2. 16 Sep 2026-8.6%

    Nothing announced by CBIO that day or the session before.

  3. 3 Sep 2026+10.0%

    Nothing announced by CBIO that day or the session before.

  4. 1 May 2026-19.2%

    Nothing announced by CBIO that day or the session before.

  5. 21 Apr 2026+13.3%
  6. 27 Mar 2026+12.3%

    Nothing announced by CBIO that day or the session before.

  7. 26 Mar 2026+14.6%

    Nothing announced by CBIO that day or the session before.

  8. 19 Feb 2026+20.8%

    Nothing announced by CBIO that day or the session before.

  9. 26 Jan 2026-8.2%

    Nothing announced by CBIO that day or the session before.

  10. 16 Jan 2026+8.1%

    Nothing announced by CBIO that day or the session before.

Share of unusual movement by asset

For each asset, the share of CBIO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
CR-001
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—96%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
PD-1 + VEGFMultispecific antibody
Solid Tumors

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
February 2029 (1)
CR-001Phase 1/2Locally Advanced / Metastatic Solid Tumors
Est. primary completion 2029-02 · NCT07335497 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 May 2024Topline resultUproleselanPivotal Phase 3 of uproleselan in R/R AML did not meet its overall survival primary endpoint
GlycoMimetics, Inc. · Source ↗

Financial reports

Quarterly & interim (17)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$3.1M$34M$289M$38M-$27M operating cash flowreport ↗
View 16 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$19M$172M$25M-$19M operating cash flowreport ↗
2026-Q1—$18M$189M$23M-$8.9M operating cash flowreport ↗
2025-Q4——$213M$23M-$27M operating cash flowreport ↗
2025-Q3—$20M$133M$25M-$18M operating cash flowreport ↗
2025-Q2—$12M$153M$22M-$22M operating cash flowreport ↗
2025-Q1—<$0.1M$5.6M$2.3M-$5.1M operating cash flowreport ↗
2024-Q3—$1.7M$14M$9.8M-$8.0M operating cash flowreport ↗
2024-Q2—$6.3M$22M$10M-$8.9M operating cash flowreport ↗
2024-Q1—$6.0M$31M$11M-$11M operating cash flowreport ↗
2023-Q3—$5.3M$49M$9.2M-$8.7M operating cash flowreport ↗
2023-Q2—$4.1M$58M$8.3M-$7.0M operating cash flowreport ↗
2023-Q1—$5.4M$65M$10M-$12M operating cash flowreport ↗
2022-Q3—$4.9M$52M$8.5M-$8.6M operating cash flowreport ↗
2022-Q2$0.1M$8.0M$60M$13M-$16M operating cash flowreport ↗
2022-Q1—$9.6M$77M$15M-$14M operating cash flowreport ↗
2021-Q3$0.1M$13M$102M$17M-$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$138M$213M$38M-$72M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$14M$11M$9.5M-$31M operating cash flowreport ↗
2023-FY<$0.1M$20M$42M$9.2M-$35M operating cash flowreport ↗
2022-FY$0.1M$28M$48M$12M-$46M operating cash flowreport ↗
2021-FY$1.2M$47M$90M$16M-$57M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($30.6M), 16 sales ($1.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-18McNeill Jonathan · President and COOOpen-market sale3,839$16.71$64KForm 4
2026-09-18Brumm Joshua T · director, Chief Executive OfficerOpen-market sale7,837$16.71$131KForm 4
2026-09-16McNeill Jonathan · President and COOOpen-market sale731$17.90$13KForm 4
2026-09-16Brumm Joshua T · director, Chief Executive OfficerOpen-market sale1,610$17.90$29KForm 4
2026-09-16Bispham Barbara Harlin · See RemarksOpen-market sale620$17.90$11KForm 4
2026-09-16Scalzo Richard William · Chief Financial OfficerOpen-market sale568$17.90$10KForm 4
2026-09-16Im Ellie Eunkyung · Chief Medical OfficerOpen-market sale623$17.90$11KForm 4
2026-09-16Pinkas Jan · Chief Scientific OfficerOpen-market sale658$17.90$12KForm 4